Yervoy's Efficacy in Key Trials
Yervoy (ipilimumab), Bristol Myers Squibb's CTLA-4 inhibitor, showed a 20% 3-year overall survival (OS) rate in the phase 3 trial for advanced melanoma versus 12% for gp100 vaccine, establishing it as the first immunotherapy to demonstrate long-term survival benefit.[1] Median OS was 10 months versus 6.4 months.
How Yervoy Compares to PD-1 Inhibitors Like Keytruda and Opdivo
PD-1 blockers outperform Yervoy alone in melanoma. Keytruda (pembrolizumab) achieved 34% 5-year OS in KEYNOTE-006 (versus 20% for Yervoy).[2] Opdivo (nivolumab) hit 52% 5-year OS in CheckMate 067 when combined with Yervoy, but nivolumab monotherapy reached 44% versus Yervoy's 27%.[3] Yervoy monotherapy has lower response rates (19% ORR) than PD-1s (33-42% ORR).
| Therapy | Melanoma ORR | 5-Year OS (Melanoma) |
|---------|--------------|----------------------|
| Yervoy monotherapy | 19% | ~20-27% |
| Keytruda monotherapy | 33% | 34% |
| Opdivo + Yervoy | 58% | 52% |
| Opdivo monotherapy | 44% | 44% |
Why Yervoy Shines in Combinations
Yervoy's strength emerges in dual checkpoint inhibition. Opdivo + Yervoy improved 4-year OS to 49% in melanoma (versus 42% Opdivo alone, 26% Yervoy alone).[3] In renal cell carcinoma, the combo hit 49% 3-year OS versus 35% for Opdivo alone in CheckMate 214.[4] It targets broader T-cell activation than PD-1s alone but with higher toxicity.
Efficacy Across Other Cancers
- Non-small cell lung cancer (NSCLC): Yervoy + Opdivo yields 14% 3-year OS in CheckMate 227 (PD-L1 ≥1%), comparable to some chemo-immuno combos but below high-PD-L1 pembrolizumab (25% 5-year OS).[5]
- MSI-H/dMMR cancers: Combo achieves 65% ORR, similar to PD-1 monotherapy but with deeper responses in some trials.[6]
Yervoy lags as monotherapy outside melanoma (e.g., failed in NSCLC solo).
What Limits Yervoy's Use Today
Higher grade 3-4 adverse events (59% with combo versus 21% PD-1 alone) reduce tolerability, leading to monotherapy preference for frail patients.[3] Progression-free survival benefits are modest without combos. No head-to-head trials exist against newer agents like bispecifics (e.g., tebotelimab).
[1] Hodi et al., NEJM 2010
[2] Robert et al., JCO 2019
[3] Larkin et al., NEJM 2019
[4] Motzer et al., NEJM 2019
[5] Hellmann et al., JCO 2020
[6] Marcus et al., JCO 2020